ML). Brown powder; yield: 74 (0.45 g); mp 19799 C. 1 H NMR (300 MHz, DMSO-d6 ) 11.78 (br.s, 1H), 7.99.91 (m, 1H), 7.48.43 (m, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.26.15 (m, 2H), six.93 (d, J = 8.7 Hz, 2H), six.65.56 (m, 2H), and 3.72 (s, 3H). 13 C NMR (75 MHz, DMSO-d6 ) 173.8, 161.4, 159.8, 136.6, 129.8, 129.four, 129.0, 125.0, 122.8, 121.4, 120.2, 114.three, 112.four, 107.0, 106.8, 82.9, and 55.1. HRMS (ESI-TOF) m/z: [M H] Calcld for C19 H15 NO3 306.1125; discovered: 306.1131. three.2. Synthesis of 4-(1H-Indol-3-yl)-3-(4-methoxybenzylidene)-5-(4-methoxyphenyl)furan-2(3H)-one six The mixture of furan-2(5H)-one 1 (1 mmol, 0.31 g), 4-methoxyaldehyde 5 (1.2 mmol, 0.16 g), and piperidine (1 mmol, 0.099 mL) was refluxed for 1 h in six mL of EtOH. The reaction mixture was cooled, filtered off and washed with EtOH (three 5 mL). Red powder; yield: 84 (0.36 g); mp 25355 C. 1 H NMR (300 MHz, DMSO-d6 ) 11.55 (br.s, 1H), 8.09 (d, J = 9.0 Hz, 2H), 7.58.47 (m, 2H), 7.35 (d, J = 9.0 Hz, 2H), 7.20.12 (m, 2H), 7.01.90 (m, 3H), 6.86.77 (m, 3H), 3.80 (s, 3H), and three.70 (s, 3H). 13 C NMR (75 MHz, DMSO-d6 ) 165.9, 161.3, 159.eight, 146.eight, 138.9, 136.5, 133.8, 127.six, 126.7, 126.0, 125.five, 121.7, 121.two, 119.five, 119.1, 114.1, 114.0, 112.1, 111.four, 111.three, 103.eight, 55.4, and 55.two. HRMS (ESI-TOF) m/z: [M H] Calcld for C27 H21 NO4 424.1543; found: 424.1539.-Irofulven medchemexpress Supplementary Supplies: The following are obtainable on the web. Copies of 1 H, 13 C-NMR, and mass spectra for compound 1 and compound six. Author Contributions: A.N.K., conceptualization, synthesis, spectroscopic evaluation, and writing on the manuscript; B.V.L., conceptualization, synthesis, spectroscopic analysis, and writing in the manuscript; V.G.M., conceptualization, synthesis, spectroscopic analysis, and writing of your manuscript. All authors have study and agreed towards the published version of the manuscript. Funding: This analysis received no external funding.Molbank 2021, 2021, M4 ofInstitutional Overview Board Statement: Not applicable. Informed Consent Statement: Not applicable. Information Availability Statement: The data for the compounds presented within this study are readily available within the Supplementary Materials of this paper. Conflicts of Interest: The authors declare no conflict of interest.
moleculesReviewCommon Components of Alzheimer’s Disease and Rheumatoid Arthritis–Pathomechanism and TreatmentPaulina Trzeciak , Mariola Herbet and Jaroslaw DudkaChair and Department of Toxicology, Faculty of Pharmacy, Health-related University of Lublin, Jaczewskiego 8b Street, 20-090 Lublin, Poland; [email protected] (P.T.); [email protected] (J.D.) Correspondence: [email protected]; Tel.: 48-81-448-Citation: Trzeciak, P.; Herbet, M.; Dudka, J.